时间：10月12日（星期四） 上午09: 00
报告人：Robert Moritz博士，美国系统生物研究所 教授；系统生物研究所蛋白质研究中心 主任
Dr. Robert Moritz is Faculty member and Head of Proteomics Research at the Institute for Systems Biology (ISB) in Seattle Washington.
He began his career at the Ludwig Institute for Cancer Research, Melbourne, Australia in 1983. From 1983 to 2008, he was appointed as proteomics research and facility manager of Joint Proteomics Laboratory of the Ludwig Institute for cancer research and The Walter and Eliza Hall Institute for medical research. From 2008 to 2010, he was appointed as associate professor and research director of Proteomics Institute for Systems Biology. From 2015 to present, he was appointed as professor and research director of Proteomics Institute for Systems Biology.
His research interests in proteomics include the discovery of normal and disease markers using targeted quantitative mass spectrometry. Specifically, his group develops proteomics tools and applies these to biomarker studies for infectious diseases, lung abnormalities and other human diseases such as kidney disease, diabetes and cancer.
The Moritz group is a primary developer of proteomics software tools and pipelines for statistical validation of proteome identifications such as the world renowned Trans-Proteomic Pipeline, protein crosslinking interpretation with the program suite Kojak and online resources for quantitative proteomics under the PeptideAtlas resource. His group has developed the complete Human Peptide and SRM-Atlas, the SWATHAtlas and software routines for SWATH data analysis to provide quantitative resources and community driven repositories of mass spectrometric assays to all proteins.
Dr. Moritz is currently the Vice-President of the Human Proteome Organization (HUPO) and plays a large role in growing the society. He has authored more than 230 papers and holds several patents in technology development and discovery protein science of the relationship of aberrant protein expression.
Systems medicine is the application of systems-biology approaches to study wellness and disease transitions. At ISB, we are integrating biology, technology and computation approaches to create a predictive, personalized, preventive and participatory approach to medicine known as P4 Medicine. I will describe our P4 pilot program—a longitudinal, digital-age study of 107 well individual and the preliminary results from these studies are striking. To support this effort, we have developed new systems and repositories. I will discuss some of these tools that are capable of generating quantitatively accurate datasets. Examples of these include our developments in targeted proteomics utilizing whole proteome resources for SRM and SWATH-MS applications to quantitative P4 Medicine. The democratization of these resources enables these tools to be routinely used and enable interrogation of biologically meaningful data so that they can be broadly collected, analyzed and shared within the community.